WPD Pharmaceuticals Inc. announced that first patient enrolled in the Phase 1B/2 clinical trial of Annamycin in the treatment of soft tissue sarcoma (STS) lung metastases, has received the first dose of Annamycin. The start of clinical trial is a consequence of the project granted by Agencja Bada Medycznych (The Medical Research Agency), that was communicated by WPD in a news release dated February 9, 2021. Agencja Bada Medycznych (The Medical Research Agency) is a Polish state agency responsible for development of scientific research in the field of medical and health sciences, awarded a grant equivalent to USD 1.5 million to the Maria Sklodowska-Curie National Research Institute to fund a Phase 1B/2 clinical trial of Annamycin for the treatment of soft tissue sarcoma (STS) lung metastases.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.045 CAD | -.--% | -.--% | -.--% |
1st Jan change | Capi. | |
---|---|---|
-.--% | 3.73M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- WBIO Stock
- News WPD Pharmaceuticals Inc.
- WPD Pharmaceuticals Inc. Announces First Patient Dosed in Phase 1B/2 Clinical Trial of Annamycin